triple hormone receptor agonist retatrutide for obesity Triple–Hormone-Receptor Agonist Retatrutide — A Phase 2 Trial # 2023年度回顧】 NEJM Notable Articles of
Description
Both medications commonly cause gastrointestinal side effects and carry important warnings
Notably, lixisenatide users had the highest risk, with a hazard ratio of 2.002 (95% CI: 1.3023.079) compared to DPP-4i users
10.1055/a-1345-7890 100 ShahM.VellaA
Research Ethics and Practices: The exploration of peptide stacks, including a mots c and retatrutide stack, should strictly adhere to ethical research guidelines, focusing on preclinical studies and data collection before considering any translation to human applications
A
Unknown Factors Effects beyond 48 weeks remain unknown until Phase 3 data becomes available
